Clinical management and burden of prostate cancer: A Markov Monte Carlo model

PLoS ONE

Volumn 9, Issue 12, 2014, Pages

  Sanyal, Chiranjeev ^a   Aprikian, Armen ^a,b   Cury, Fabio ^a,c   Chevalier, Simone ^a,b   Dragomir, Alice ^a,b  

^a MCGILL UNIVERSITY   (Canada)

^b RESEARCH INSTITUTE OF THE MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

^c MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ACCURACY; ANDROGEN DEPRIVATION THERAPY; ARTICLE; BRACHYTHERAPY; CANCER MORTALITY; CANCER RECURRENCE; CANCER RISK; CASTRATION RESISTANT PROSTATE CANCER; HUMAN; INTENSITY MODULATED RADIATION THERAPY; MARKOV MONTE CARLO MODEL; OUTCOME ASSESSMENT; PROSTATE CANCER; PROSTATECTOMY; SENSITIVITY ANALYSIS; SIMULATION; STATISTICAL MODEL; TERMINAL CARE; VALIDATION PROCESS; AGED; BIOLOGICAL MODEL; COHORT ANALYSIS; DISEASE FREE SURVIVAL; HEALTH STATUS; LIFE EXPECTANCY; MALE; MONTE CARLO METHOD; MORTALITY; PATHOLOGY; PROBABILITY; PROSTATIC NEOPLASMS; RISK; TUMOR RECURRENCE; VERY ELDERLY;

AGED; AGED, 80 AND OVER; COHORT STUDIES; DISEASE-FREE SURVIVAL; HEALTH STATUS; HUMANS; LIFE EXPECTANCY; MALE; MARKOV CHAINS; MODELS, BIOLOGICAL; MONTE CARLO METHOD; NEOPLASM RECURRENCE, LOCAL; OUTCOME ASSESSMENT (HEALTH CARE); PROSTATIC NEOPLASMS; RISK;

EID: 84956663836     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0113432     Document Type: Article

References (72)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, et al. (2011) Global cancer statistics. CA Cancer J Clin 61: 69-90.
2. Canadian Cancer Statistics (2013) Available at http://www.cancer.ca/en/cancer-information/cancer-101/canadian-cancer-statistics-publication/?region5qc. Accessed on August 14, 2013.
3. Rodrigues G, Warde P, Pickles T, Crook J, Brundage M, et al. (2012) Pre-treatment risk stratification of prostate cancer patients: A critical review. Can Urol Assoc J 6: 121-127.
4. Hotte SJ, Saad F (2010) Current management of castrate-resistant prostate cancer. Curr Oncol 1 Suppl 2: S72-79.
5. Saad F, Hotte S, Catton C, Drachenberg D, Finelli A, et al. (2013) CUA-CUOG guidelines for the management of castration-resistant prostate cancer (CRPC): 2013 update. Can Urol Assoc J 7: 231-237.
6. Oudard S (2012) Progress in emerging therapies for advanced prostate cancer. Cancer Treat Rev 39: 275-289.
7. American Urological Association guideline for the management of Castration Resistant Prostate Cancer. Available at http://www.auanet.org/education/guidelines/castration-resistant-prostate-cancer.cfm. Accessed on July 8, 2013.
8. National Comprehensive Cancer Network Guidelines. Available at http://www.nccn.org/professionals/physician-gls/f-guidelines.asp#site. Accessed on August 14, 2013.
9. Grover SA, Coupal L, Zowall H, Rajan R, Trachtenberg J, et al. (2000) The clinical burden of prostate cancer in Canada: forecasts from the Montreal Prostate Cancer Model. CMAJ 162: 977-983.
10. Cowen ME, Chartrand M, Weitzel WF (1994) A Markov model of the natural history of prostate cancer. J Clin Epidemiol 47: 3-21.
11. Fleming C, Wasson JH, Albertsen PC, Barry MJ, Wennberg JE (1993) A decision analysis of alternative treatment strategies for clinically localized prostate cancer. Prostate Patient Outcomes Research Team. Jama 269: 2650-2658.
12. AlDuhaiby EZ, Breen S, Bissonnette JP, Sharpe M, Mayhew L, et al. (2012) A national survey of the availability of intensity-modulated radiation therapy and stereotactic radiosurgery in Canada. Radiat Oncol 7: 18.
13. Drummond MF, Sculpher MJ, Torrance GW, O'Brien BJ, Stoddart GL, et al. (2005) Methods for the economic evaluation of health care programme. Third edition: Oxford: Oxford University Press.
14. Hunink MGM, Glasziou PP, Siegel JE, Weeks JC, Pliskin JS, et al. (2001) Decision Making in Health and Medicine: Interpreting Evidence and Values. Cambridge: Cambridge University Press.
15. Ficarra V, Novara G, Artibani W, Cestari A, Galfano A, et al. (2009) Retropubic, laparoscopic, and robot-assisted radical prostatectomy: a systematic review and cumulative analysis of comparative studies. Eur Urol 55: 1037-1063.
16. Pierorazio PM, Mullins JK, Eifler JB, Voth K, Hyams ES, et al. (2013) Contemporaneous comparison of open vs minimally-invasive radical prostatectomy for high-risk prostate cancer. BJU Int.
17. Vora SA, Wong WW, Schild SE, Ezzell GA, Andrews PE, et al. (2013) Outcome and toxicity for patients treated with intensity modulated radiation therapy for localized prostate cancer. J Urol 190: 521-526.
18. Klotz L, Zhang L, Lam A, Nam R, Mamedov A, et al. (2009) Clinical results of long-term follow-up of a large, active surveillance cohort with localized prostate cancer. J Clin Oncol 28: 126-131.
19. Aizer AA, Yu JB, Colberg JW, McKeon AM, Decker RH, et al. (2009) Radical prostatectomy vs. intensity-modulated radiation therapy in the management of localized prostate adenocarcinoma. Radiother Oncol 93: 185-191.
20. Kotecha R, Yamada Y, Pei X, Kollmeier MA, Cox B, et al. (2012) Clinical outcomes of high-dose-rate brachytherapy and external beam radiotherapy in the management of clinically localized prostate cancer. Brachytherapy 12: 44-49.
21. Crook JM, O'Callaghan CJ, Duncan G, Dearnaley DP, Higano CS, et al. (2012) Intermittent androgen suppression for rising PSA level after radiotherapy. N Engl J Med 367: 895-903.
22. Dragomir A, Dinea D, Vanhuyse M, Cury FL, Aprikian AG (2014) Drug costs in the management of metastatic castration-resistant prostate cancer in Canada. BMC Health Serv Res 14: 252.
23. Siebert U, Alagoz O, Bayoumi AM, Jahn B, Owens DK, et al. (2012) State-transition modeling: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force-3. Value Health 15: 812-820.
24. Cooperberg MR, Broering JM, Kantoff PW, Carroll PR (2007) Contemporary trends in low risk prostate cancer: risk assessment and treatment. J Urol 178: S14-19.
25. Carter HB (2012) Active surveillance for prostate cancer: an underutilized opportunity for reducing harm. J Natl Cancer Inst Monogr 2012: 175-183.
26. Keegan KA, Dall'Era MA, Durbin-Johnson B, Evans CP (2011) Active surveillance for prostate cancer compared with immediate treatment: an economic analysis. Cancer 118: 3512-3518.
27. Zelefsky MJ, Eastham JA, Cronin AM, Fuks Z, Zhang Z, et al. (2010) Metastasis after radical prostatectomy or external beam radiotherapy for patients with clinically localized prostate cancer: a comparison of clinical cohorts adjusted for case mix. J Clin Oncol 28: 1508-1513.
28. Mortality, Summary List of Causes. Available at http://www.statcan.gc.ca/pub/84f0209x/84f020962008000-eng.pdf. Accessed on October 7, 2013.
29. Pataky R, Gulati R, Etzioni R, Black P, Chi KN, et al. (2014) Is prostate cancer screening costeffective? A microsimulation model of prostate-specific antigen-based screening for British Columbia, Canada. Int J Cancer.
30. TreeAge Software Inc, Williamstown MA, USA. Available at https://www.treeage.com/. Accessed on December 7, 2013.
31. Eddy DM, Hollingworth W, Caro JJ, Tsevat J, McDonald KM, et al. (2012) Model transparency and validation: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force-7. Value Health 15: 843-850.
32. Kopec JA, Fines P, Manuel DG, Buckeridge DL, Flanagan WM, et al. (2010) Validation of populationbased disease simulation models: a review of concepts and methods. BMC Public Health 10: 710.
33. Report on the Demographic Situation in Canada. Mortality: Overview, (2000 and 2011) Available at http://www.statcan.gc.ca/pub/91-209-x/2013001/article/11867-eng.htm. Accessed on May 12,2014.
34. OECD (2013), Health at a Glance 2013: OECD Indicators, OECD Publishing. Available at http://dx.doi.org/10.1787/health-glance-2013-en. Accessed on May 12,2014.
35. Statistics Canada. Table 102-0122-Health-adjusted life expectancy, at birth and at age 65, by sex and income, Canada and provinces, occasional (years) Available at http://www5.statcan.gc.ca/cansim/a05. Accessed on May 12,2014.
36. Alicikus ZA, Yamada Y, Zhang Z, Pei X, Hunt M, et al. (2011) Ten-year outcomes of high-dose, intensity-modulated radiotherapy for localized prostate cancer. Cancer 117: 1429-1437.
37. Roehl KA, Han M, Ramos CG, Antenor JA, Catalona WJ (2004) Cancer progression and survival rates following anatomical radical retropubic prostatectomy in 3,478 consecutive patients: long-term results. J Urol 172: 910-914.
38. van den Bergh RC, Roemeling S, Roobol MJ, Aus G, Hugosson J, et al. (2008) Outcomes of men with screen-detected prostate cancer eligible for active surveillance who were managed expectantly. Eur Urol 55: 1-8.
39. Astrom L, Pedersen D, Mercke C, Holmang S, Johansson KA (2005) Long-term outcome of high dose rate brachytherapy in radiotherapy of localised prostate cancer. Radiother Oncol 74: 157-161.
40. Eggener SE, Scardino PT, Walsh PC, Han M, Partin AW, et al. (2011) Predicting 15-year prostate cancer specific mortality after radical prostatectomy. J Urol 185: 869-875.
41. Merino T, San Francisco IF, Rojas PA, Bettoli P, Zuniga A, et al. (2013) Intensity-modulated radiotherapy versus radical prostatectomy in patients with localized prostate cancer: long-term follow-up. BMC Cancer 13: 530.
42. Galalae RM, Martinez A, Mate T, Mitchell C, Edmundson G, et al. (2004) Long-term outcome by risk factors using conformal high-dose-rate brachytherapy (HDR-BT) boost with or without neoadjuvant androgen suppression for localized prostate cancer. Int J Radiat Oncol Biol Phys 58: 1048-1055.
43. Prada PJ, Mendez L, Fernandez J, Gonzalez H, Jimenez I, et al. (2012) Long-term biochemical results after high-dose-rate intensity modulated brachytherapy with external beam radiotherapy for high risk prostate cancer. Radiat Oncol 7: 31.
44. Tosoian JJ, Trock BJ, Landis P, Feng Z, Epstein JI, et al. (2011) Active surveillance program for prostate cancer: an update of the Johns Hopkins experience. J Clin Oncol 29: 2185-2190.
45. D'Amico AV, Whittington R, Malkowicz SB, Schultz D, Blank K, et al. (1998) Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA 280: 969-974.
46. D'Amico AV, Moul JW, Carroll PR, Sun L, Lubeck D, et al. (2003) Surrogate end point for prostate cancer-specific mortality after radical prostatectomy or radiation therapy. J Natl Cancer Inst 95: 1376-1383.
47. Zelefsky MJ, Pei X, Chou JF, Schechter M, Kollmeier M, et al. (2011) Dose escalation for prostate cancer radiotherapy: predictors of long-term biochemical tumor control and distant metastases-free survival outcomes. Eur Urol 60: 1133-1139.
48. Stephenson AJ, Kattan MW, Eastham JA, Dotan ZA, Bianco FJ Jr, et al. (2006) Defining biochemical recurrence of prostate cancer after radical prostatectomy: a proposal for a standardized definition. J Clin Oncol 24: 3973-3978.
49. Han M, Partin AW, Pound CR, Epstein JI, Walsh PC (2001) Long-term biochemical disease-free and cancer-specific survival following anatomic radical retropubic prostatectomy. The 15-year Johns Hopkins experience. Urol Clin North Am 28: 555-565.
50. D'Amico AV, Cote K, Loffredo M, Renshaw AA, Schultz D (2002) Determinants of prostate cancerspecific survival after radiation therapy for patients with clinically localized prostate cancer. J Clin Oncol 20: 4567-4573.
51. Freedland SJ, Humphreys EB, Mangold LA, Eisenberger M, Dorey FJ, et al. (2005) Risk of prostate cancer-specific mortality following biochemical recurrence after radical prostatectomy. JAMA 294: 433-439.
52. Sooriakumaran P, Nyberg T, Akre O, Haendler L, Heus I, et al. (2014) Comparative effectiveness of radical prostatectomy and radiotherapy in prostate cancer: observational study of mortality outcomes. BMJ 348: g1502.
53. Sathya JR, Davis IR, Julian JA, Guo Q, Daya D, et al. (2005) Randomized trial comparing iridium implant plus external-beam radiation therapy with external-beam radiation therapy alone in nodenegative locally advanced cancer of the prostate. J Clin Oncol 23: 1192-1199.
54. Efstathiou JA, Bae K, Shipley WU, Hanks GE, Pilepich MV, et al. (2008) Cardiovascular mortality and duration of androgen deprivation for locally advanced prostate cancer: analysis of RTOG 92-02. Eur Urol 54: 816-823.
55. Smith MR, Bae K, Efstathiou JA, Hanks GE, Pilepich MV, et al. (2008) Diabetes and mortality in men with locally advanced prostate cancer: RTOG 92-02. J Clin Oncol 26: 4333-4339.
56. Keating NL, O'Malley AJ, Freedland SJ, Smith MR (2009) Diabetes and cardiovascular disease during androgen deprivation therapy: observational study of veterans with prostate cancer. J Natl Cancer Inst 102: 39-46.
57. Keating NL, O'Malley AJ, Smith MR (2006) Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer. J Clin Oncol 24: 4448-4456.
58. Azoulay L, Yin H, Benayoun S, Renoux C, Boivin JF, et al. (2011) Androgen-deprivation therapy and the risk of stroke in patients with prostate cancer. Eur Urol 60: 1244-1250.
59. Bensimon L, Yin H, Suissa S, Pollak MN, Azoulay L (2014) Type 2 diabetes and the risk of mortality among patients with prostate cancer. Cancer Causes Control 25: 329-338.
60. Yu O, Eberg M, Benayoun S, Aprikian A, Batist G, et al. (2013) Use of statins and the risk of death in patients with prostate cancer. J Clin Oncol 32: 5-11.
61. Drummond MF, Bloom BS, Carrin G, Hillman AL, Hutchings HC, et al. (1992) Issues in the crossnational assessment of health technology. Int J Technol Assess Health Care 8: 671-682.
62. Hogendoorn W, Schlosser FJ, Moll FL, Muhs BE, Hunink MG, et al. (2013) Decision analysis model of open repair versus endovascular treatment in patients with asymptomatic popliteal artery aneurysms. J Vasc Surg 59: 651-662.
63. Siebert U, Sroczynski G, Hillemanns P, Engel J, Stabenow R, et al. (2006) The German cervical cancer screening model: development and validation of a decision-analytic model for cervical cancer screening in Germany. Eur J Public Health 16: 185-192.
64. van Kempen BJ, Ferket BS, Hofman A, Steyerberg EW, Colkesen EB, et al. (2012) Validation of a model to investigate the effects of modifying cardiovascular disease (CVD) risk factors on the burden of CVD: the rotterdam ischemic heart disease and stroke computer simulation (RISC) model. BMC Med 10: 158.
65. Spratt DE, Pei X, Yamada J, Kollmeier MA, Cox B, et al. (2013) Long-term survival and toxicity in patients treated with high-dose intensity modulated radiation therapy for localized prostate cancer. Int J Radiat Oncol Biol Phys 85: 686-692.
66. Zelefsky MJ, Kuban DA, Levy LB, Potters L, Beyer DC, et al. (2006) Multi-institutional analysis of long-term outcome for stages T1-T2 prostate cancer treated with permanent seed implantation. Int J Radiat Oncol Biol Phys 67: 327-333.
67. Spratt DE, Zumsteg ZS, Ghadjar P, Kollmeier MA, Pei X, et al. (2014) Comparison of high-dose (86. Gy) IMRT vs combined brachytherapy plus IMRT for intermediate-risk prostate cancer. BJU Int.
68. Deutsch I, Zelefsky MJ, Zhang Z, Mo Q, Zaider M, et al. (2010) Comparison of PSA relapse-free survival in patients treated with ultra-high-dose IMRT versus combination HDR brachytherapy and IMRT. Brachytherapy 9: 313-318.
69. Stone NN, Stock RG, Cesaretti JA, Unger P (2009) Local control following permanent prostate brachytherapy: effect of high biologically effective dose on biopsy results and oncologic outcomes. Int J Radiat Oncol Biol Phys 76: 355-360.
70. U.S. Population by Age: July 1, 2010. (2010) National Tables and Trends. Available at http://www.aoa.gov/AoARoot/Aging-Statistics/Census-Population/census2010/Index.aspx. Accessed on May 12,2014.
71. Deaths, Percent of Total Deaths, and Death Rates for the 15 Leading Causes of Death in 5-year Age Groups, by Race and Sex: United States (1999-2010) Available at http://www.cdc.gov/nchs/nvss/mortality/lcwk1.htm. Accessed on May 12,2014.
72. Tannock IF, de Wit R, Berry WR, Horti J, Pluzanska A, et al. (2004) Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 351: 1502-1512.